Login to Your Account

U3 Pharma Raises EUR 27M For Preclinical Cancer Products

By Cormac Sheridan

Wednesday, May 24, 2006
U3 Pharma AG raised €27 million (US$34.7 million) to accelerate development of its pipeline of targeted therapies, designed to modulate signal transduction pathways in cancer. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription